Cevipabulin (0-50 nM, 72 hours) shows good activity (IC50s: 18~40 nM) on cell lines from ovarian, breast, prostate, and cervical tumors. Cevipabulin at low concentrations (20-40 nM) produces sub-G1 nuclei and, at concentrations above 50 nM, it causes a strong G2-M block [1].

In mice, Cevipabulin ( 5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles; i.v. and p.o.) is active against human tumor xenografts and showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg [1].